A biotech company that receives funding from Merck, Eli Lilly, and the personal equity firm BlackRock claims to have started one of the first human scientific studies for a medicine that was discovered using artificial intelligence to analyse a vast database of brain tissue.
Verge Genomics, which was founded by Alice Zhang, a 33-year-old former University of California neuroscience doctoral student, informed the Financial Times that it had dosed its first patient with a novel treatment called VRG50635, aimed at ALS, a neurodegenerative disease for which there isn’t a known cure.
The San Francisco-based company is one of a new generation of biotechs using AI technology in drug discovery, a quickly expanding industry that continues to draw billions of dollars in venture money despite a collapse in sector values.
AI systems can swiftly identify therapeutic targets — bodily proteins linked to specific diseases — and chemicals that could be turned into medications by crunching enormous amounts of data. According to experts, the technology can shorten the time it takes for a treatment to move from initial discovery to approval, lower the costs of improvement, and lower the high failure rate in scientific studies.
Last year, Verge collected $98 million from well-known investors to further its ALS research and drug development efforts. It has entered into a relationship with Lilly to create treatments for a related disease. Verge paid a $25 million upfront payment for this agreement, and if certain milestones are reached, additional funds worth $694 million in royalties and milestone funds could become available.
According to Morgan Stanley, which predicted in a June research that the technology would increase the viability of early-stage drug development and will deliver an extra 50 medicines within 10 years, Big Pharma and investors are vying for a $50 billion opportunity in AI over the coming decade.
Recently, a number of biotech companies, including Exscientia, Evotec, and Insilico Drugs, released medications discovered or created using AI that have advanced to clinical trials.
Zhang stated in an interview that it took Verge 4 years to complete the discovery process and begin clinical testing for its ALS treatment. She said, compared to conventional drug development methods, which frequently relied on trial and error, this is quicker and less expensive.
To predict which of those medicines would actually work in people, speculation is frequently derived from educational findings or papers and explored sequentially, primarily in animals, mice, and even cell models. Many tens of thousands of dollars later, you might be entering clinical trials, and the medicine fails, which is to be expected,” said Zhang.
“If we want to reach individuals, we’re saying why not start with them right now and use an information-driven strategy?”
Verge has created a library of human tissues from patients with neurodegenerative diseases like ALS, Parkinson’s, and Alzheimer’s brains and spinal cords. Through DNA sequencing, it has produced what it refers to as a “human ailment map,” which will be mined by its AI platform to identify treatment targets for disease.
Verge claimed that after analysing more than 11.4 million data points, it discovered a novel ALS causal mechanism—the loss of endolysosomal function that affects human cells—which revealed a possible new therapy target.
Zhang stated that Verge’s approach eliminates the need to conduct large-scale tests or screen hundreds of medications and potential disease targets. Utilizing human data from the start means that we start with higher-quality goals that are more likely to be reached in the clinic, she explained.
Success, according to consultants, is far from guaranteed. The most challenging illnesses are the target of Verge’s initial medicine that is currently undergoing trials. Over the past 20 years, there have been no fewer than 50 research experiments on ALS medicines, and none of them have shown promising results. Only three medications have been approved in the US, and these have only modestly benefited patients.
Alix Lacoste, AI computational biology director at Invitae, a genetic testing company, stated that “animal models have proven poor predictors of efficacy in scientific studies for neurodegenerative disorders.”
Verge is somewhat unique in that it uses AI to analyse user data rather than relying on animal models, according to the speaker.
